CHMP recommends approval of Atara Biotherapeutics’ Ebvallo (tabelecleucel) for the treatment of Epstein-Barr virus positive post transplant lymphoproliferative disease

Atara Biotherapeutics

14 October 2022 - Ebvallo on track to be the first ever allogeneic T-cell therapy approved.

Atara Biotherapeutics and Pierre Fabre today announced the CHMP of the EMA has adopted a positive opinion recommending the European Commission approval of Ebvallo (tabelecleucel) as a monotherapy for treatment of adult and paediatric patients two years of age and older with relapsed or refractory Epstein‑Barr virus positive post‑transplant lymphoproliferative disease, who have received at least one prior therapy.

Read Atara Biotherapeutics press release

Michael Wonder

Posted by:

Michael Wonder